Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EA-3
- Development stage
- Preclinical
- Lead developer
- Endo Axiom
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral
01
Overview
EA-3 is a discovery-stage nucleic-acid therapeutic program being developed by Endo Axiom for the treatment of Haemophilia A. The program utilizes a proprietary quantum-dot (QD) enabled delivery platform designed to facilitate the oral administration of various nucleic acid modalities, including messenger RNA (mRNA), small interfering RNA (siRNA), and microRNA (miRNA). By employing this nanoparticle-based delivery system, EA-3 aims to enable the oral absorption of therapeutic genetic material, which typically requires parenteral administration. While the specific molecular target or genetic construct has not been disclosed, the program is intended to address the underlying pathology of Haemophilia A through the oral delivery of functional or regulatory nucleic acids.
- Other names
- Nucleic-acid therapeutics programme
Beyond the preview
Go deeper on EA-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EA-3.